EPCORE® DLBCL-3 Trial Results Separately, new results from the ongoing Phase 2 EPCORE DLBCL-3 trial (abstract 63), for fixed-duration epcoritamab monotherapy in newly diagnosed elderly patients with ...

Data suggest stronger immune fitness in earlier lines may be associated with longer progression-free survival2 BEERSE, BELGIUM, Dec. 06, 2025 (GLOBE NEWSWIRE) -- Johnson & Johnson today announced ...

The Company has completed GLP toxicology studies and anticipates filing the IND and initiating a phase 1 study in the first quarter of 2026. The Company’s JAK2V617F inhibitor program is subject to an ...

Following completion of the 24-week treatment period, patients had the option to receive bezuclastinib in an open-label extension study. Baseline patient demographics were balanced between treatment ...

Lisaftoclax achieved a 62.5% objective response rate (ORR) in heavily pretreated, BTKi-refractory patients, nearly half with complex karyotype Lisaftoclax monotherapy demonstrated a median progression ...

DISC-0974 was generally well-tolerated. Diarrhea and urinary tract infections, neither considered serious, were the only adverse events (AE) that were considered related to DISC-0974 and reported in ...

The totality of the data suggests that a higher dose of ficerafusp alfa with greater TGF-β inhibition and immune activation drives deeper tumor responses that translate to more durable outcomes for ...

TUS+VEN+AZA triplet frontline therapy demonstrates high rates of efficacy and MRD-negative remissions in newly diagnosed AML patients with diverse mutations; Safety continues to b ...

Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and ...

Pivotal Phase 3 ARISE trial evaluating solengepras as an adjunctive treatment in Parkinson’s disease is underway and actively enrolling patients BOSTON, Dec. 05, 2025 (GLOBE NEWSWIRE) -- Cerevance, a ...

Preliminary Activity Analysis In the 15 efficacy-evaluable patients in the 120 mg cohort, the majority of which received an effective dose of 80 mg QD, enozertinib demonstrated strong systemic and CNS ...

KALA BIO, Inc. (NASDAQ:KALA) (“KALA” or the “Company”), today announced the closing of its previously announced registered direct offering priced at-the-market under Nasdaq rules for the purchase of ...